MedTrace Logo

Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy

NCT01525888 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-06-08

No results posted yet for this study

Summary

The aim of the current study is to evaluate prospectively whether concomitant administration of renin-angiotensin-aldosterone system (RAAS) blockers (namely ACE-I and ARBs') influence the change in estimated glomerular filtration rate or GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Conditions

  • Radiographic Contrast Agent Nephropathy

Interventions

PROCEDURE

stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)

stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker

Sponsors & Collaborators

  • Soroka University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-12-31
Completion
2013-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01525888 on ClinicalTrials.gov